Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $134.6 million versus the consensus estimate of $130.43 million.

GUIDANCE:

Acadia Pharma sees FY2022 revenue of $510-540 million, versus the consensus of $531 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.